Delivery Order SPE2DB20D2014-SPE2DB24FC43Z

Award Date 7/10/24
Potential Completion Date 7/11/24
Potential Value $4.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of the medication Bydureon BCISE 2 mg auto-injectors. The $2,649.94 firm-fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency, and has a completion date of May 31, 2024. The contract is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of Bydureon BCISE 2 mg autoinjector 0.85 ml. The $5,662.56 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency, on May 25, 2023, with a completion date of May 26, 2023. The contract is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of Bydureon BCISE 2 mg autoinjector 0.85 ml. The award, valued at $1,677.69, is a firm-fixed-price delivery order with a completion date of December 16, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $3,308.31 firm fixed price delivery order is for the supply of Bydureon Bcise, a 2 mg autoinjected medication used to treat type 2 diabetes. The contract has a completion date of June 27, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Bydureon BCISE 2 mg autoinjector 0.85 ml. The $7,360.40 fixed-price delivery order has a completion date of May 8, 2023. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, running through November 2026, which serves as a...
This federal contract award to Amerisourcebergen Drug Corp is for the delivery of the pharmaceutical product Bydureon BCISE 2 MG Autoinjector 0.85ML. The contract, valued at $4,614.39, was awarded by the Defense Logistics Agency (DLA) under a Delivery Order with a Firm Fixed Price pricing type. The contract has an ultimate completion date of November 20, 2024. Amerisourcebergen, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,050.04 firm fixed-price delivery order is for the supply of Bydureon BCISE 2 mg autoinjectors. The contract has a period of performance through May 31, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award, valued at $4,735.50, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of the pharmaceutical product Bydureon BCISE 2 mg Auto-Injector 0.85 mL. Amerisourcebergen, a major pharmaceutical distribution company, holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued up to $999,999,999.00 through December 2025. This single-award IDC serves as the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Bydureon BCISE 2 mg autoinjectors. The contract has a ceiling value of $1,563.16 and is a firm fixed-price delivery order with a completion date of May 26, 2023. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999, which serves as a primary vehicle for...
This contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Bydureon Bcise 2 mg autoinjectors. The $9,706.56 firm-fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical...
  • SPE2DB20D2014
    Indefinite Delivery Contract
  • SPE2DB20D2014-SPE2DB24FC43Z
    Delivery Order

This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of the medication Bydureon BCISE 2 mg autoinjector 0.85 ml. The $4,710.60 firm fixed price delivery order was issued by the Defense Logistics Agency (DLA), a logistics combat support agency for the U.S. Department of Defense.

Amerisourcebergen also holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999.00 through December 2025, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. Additionally, the company has a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024. This contract award does not have a socioeconomic set-aside designation.

Generated 10/9/24, 9:08 AM